



RECEIVED

NOV 02 2001

TECH CENTER 1600/2900

PATENT

ATTORNEY DOCKET NO. 07004/002002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Jong Y. Lee
Serial No.: 09/016,159
Filed : January 30, 1998
Title : PURIFIED HUMAN ERYTHROPOIETIN RECEPTOR PROTEIN
FRAGMENT AND ANTIBODIES DERIVED THEREFROM

Art Unit: 1646
Examiner:

Assistant Commissioner for Patents
Washington, DC 20231

NOTIFICATION OF ERROR ON FILING RECEIPT

Dear Sir:

We received a Filing Receipt for the above-noted case. The Filing Receipt does not include the complete continuing data for this patent application. The correct continuing data should be:

This application is a continuation of U.S. application serial no. 08/876,227, filed June 16, 1997, which is a continuation of U.S. application serial no. 08/734,097, filed October 21, 1996, which is a continuation of U.S. application serial no. 08/460,525, filed June 2, 1995, which is a divisional of U.S. application serial no. 08/106,815, filed August 16, 1993.

If there are any charges, or any credits, please apply them to Deposit Account 06-1050.

Respectfully submitted,

Date: March 20, 1998

Mark S. Ellinger
Mark S. Ellinger, Ph.D.
Reg. No. 34,812

Fish & Richardson P.C., P.A.
60 South Sixth Street, Suite 3300
Minneapolis, MN 55402

Telephone: 612/335-5070
Facsimile: 612/288-9696
13738.M11

Date of Deposit March 20, 1998
I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Julie Erickson
Julie Erickson



UNITED STATES PATENT AND TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

07004-002004


APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/016,159	01/30/1998	1647	605	07004 002002	6	7	4

CONFIRMATION NO. 6621

CORRECTED FILING RECEIPT



OC000000006494537

 FISH & RICHARDSON P.C., P.A.
 60 SOUTH SIXTH STREET
 SUITE 3300
 MINNEAPOLIS, MN 55402


Date Mailed: 08/29/2001

Receipt is acknowledged of a CPA in this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

JONG Y. LEE, MINNEAPOLIS, MN;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CONTINUATION OF 08/876,227 06/16/1997 ABN

Foreign Applications

If Required, Foreign Filing License Granted 03/06/1998

CPA filed on: 04/26/2001

Projected Publication Date: 12/06/2001

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

 PURIFIED HUMAN ERYTHROPOIETIN RECEPTOR PROTEIN FRAGMENT AND ANTIBODIES
 DERIVED THEREFROM

Preliminary Class

435

Data entry by : NGUYEN, TRAC

Team : OIPE

Date: 08/29/2001

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231



Creation date: 01-05-2004
Indexing Officer: TDANG5 - TIEN DANG
Team: OIPEBackFileIndexing
Dossier: 09016159

Legal Date: 12-31-2001

No.	Doccode	Number of pages
1	LET.	4

Total number of pages: 4

Remarks:

Order of re-scan issued on